Page
%P
![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Open AccessDurable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma
-
Chapter
Infections in Patients with Hematologic Malignancies Treated with Monoclonal Antineoplastic Therapy
The advent of monoclonal antibody therapy heralded a new era in oncology. In 1997, rituximab became the first monoclonal antibody for the treatment of cancer following its approval for patients with B-cell non...